H.C. Wainwright raised the firm’s price target on Vir Biotechnology to $110 from $85 and keeps a Buy rating on the shares. The company appears well positioned for the coming chronic hepatitis B virus infection “boom,” the analyst tells investors in a research note. The firm increased its revenue estimates for Vir’s chronic hepatitis B virus franchise, which is the primary driver of the price target increase.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VIR:
- Vir Biotechnology downgraded to Neutral from Overweight at JPMorgan
- Vir Biotechnology price target lowered to $85 from $95 at H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com